现代肿瘤医学
現代腫瘤醫學
현대종류의학
JOURNAL OF MODERN ONCOLOGY
2009年
8期
1415-1418
,共4页
李文新%张秀敏%胡沛臻%隋延仿%师建国%王军伟%史琪琪
李文新%張秀敏%鬍沛臻%隋延倣%師建國%王軍偉%史琪琪
리문신%장수민%호패진%수연방%사건국%왕군위%사기기
肝癌转移%SCID小鼠%免疫重建%动物模型
肝癌轉移%SCID小鼠%免疫重建%動物模型
간암전이%SCID소서%면역중건%동물모형
metastatic hepatocelluar carcinoma%SCID mice%immune reconstruction%animal mode1
目的:建立具有人免疫学特性的高转移肝癌SCID 鼠模型.方法:SCID小鼠腹腔注射人外周血淋巴细胞,皮下接种人高转移肝癌细胞MHCC97-H,免疫重建人高转移肝癌SCID小鼠模型,并鉴定建立的结果.结果:①免疫重建荷人高转移肝癌细胞小鼠的成瘤率为100% ,较荷瘤组成瘤潜伏期延长,体积缩小( P<0.05);转移率为100%,其从皮下转移到肝脏所需时间较荷瘤组延长(P<0.05).②第2、4、6周小鼠血中人IgG含量的测定:同期相比,人化荷瘤组小鼠血中人IgG含量高于人化组(P<0.05). ③第6周SCID小鼠外周血中人CD3+T淋巴细胞和人CD20+ B淋巴细胞含量的测定:人化荷瘤组小鼠血中人CD3+T淋巴细胞和人CD20+ B淋巴细胞含量高于人化组(P<0.05).④免疫组化检测人化荷瘤组小鼠脾脏中存在人CD3+ T 淋巴细胞和CD20+ B淋巴细胞.结论:成功建立免疫重建荷人高转移肝癌SCID 鼠模型,为肝癌转移的研究及治疗提供了理想的动物模型.
目的:建立具有人免疫學特性的高轉移肝癌SCID 鼠模型.方法:SCID小鼠腹腔註射人外週血淋巴細胞,皮下接種人高轉移肝癌細胞MHCC97-H,免疫重建人高轉移肝癌SCID小鼠模型,併鑒定建立的結果.結果:①免疫重建荷人高轉移肝癌細胞小鼠的成瘤率為100% ,較荷瘤組成瘤潛伏期延長,體積縮小( P<0.05);轉移率為100%,其從皮下轉移到肝髒所需時間較荷瘤組延長(P<0.05).②第2、4、6週小鼠血中人IgG含量的測定:同期相比,人化荷瘤組小鼠血中人IgG含量高于人化組(P<0.05). ③第6週SCID小鼠外週血中人CD3+T淋巴細胞和人CD20+ B淋巴細胞含量的測定:人化荷瘤組小鼠血中人CD3+T淋巴細胞和人CD20+ B淋巴細胞含量高于人化組(P<0.05).④免疫組化檢測人化荷瘤組小鼠脾髒中存在人CD3+ T 淋巴細胞和CD20+ B淋巴細胞.結論:成功建立免疫重建荷人高轉移肝癌SCID 鼠模型,為肝癌轉移的研究及治療提供瞭理想的動物模型.
목적:건립구유인면역학특성적고전이간암SCID 서모형.방법:SCID소서복강주사인외주혈림파세포,피하접충인고전이간암세포MHCC97-H,면역중건인고전이간암SCID소서모형,병감정건립적결과.결과:①면역중건하인고전이간암세포소서적성류솔위100% ,교하류조성류잠복기연장,체적축소( P<0.05);전이솔위100%,기종피하전이도간장소수시간교하류조연장(P<0.05).②제2、4、6주소서혈중인IgG함량적측정:동기상비,인화하류조소서혈중인IgG함량고우인화조(P<0.05). ③제6주SCID소서외주혈중인CD3+T림파세포화인CD20+ B림파세포함량적측정:인화하류조소서혈중인CD3+T림파세포화인CD20+ B림파세포함량고우인화조(P<0.05).④면역조화검측인화하류조소서비장중존재인CD3+ T 림파세포화CD20+ B림파세포.결론:성공건립면역중건하인고전이간암SCID 서모형,위간암전이적연구급치료제공료이상적동물모형.
Objective:To explore the effective methods of establishing a human metastatic hepatocelluar carcinoma model in human peripheral blood lymphocyte (hu-PBL) engrafted to severe combined immunodeficient (SCID) mice.Methods:The immunological features of mice were evaluated after intra-peritoneal injection of hu-PBL and subcutaneous implantation of human high metastatic hepatocelluar carcinoma cells (MHCC97-Hs).Results:①Subcutaneous tumors developed in all the mice given hu-PBL and MHCC97-Hs.The latency period was significantly prolonged,and the tumor size was marked depressed,as compared with mice given human MHCC97-Hs alone.The tumor's metastatic time needed of the mice given hu-PBL and MHCC97-Hs was longer than the mice given human MHCC97-Hs alone.②In the 2nd,4th and 6th week,the amount of human IgG in the mice given hu-PBL and MHCC97-Hs was lager than the mice given MHCC97-Hs alone.③In the 6th week,the number of human CD3+ T lymphocytes and CD20+ B lymphocytes in the mice given hu-PBL and MHCC97-Hs was lager than the mice MHCC97-Hs alone.④Immunohistochemical staining revealed presence of remarkable human CD3+ T lymphocytes and CD20+ B lymphocytes in SCID mice spleen.Conclusion:A human high metastatic hepatocelluar carcinoma model has been established hu-PBL engrafted to SCID mice,which is an ideal animal model for preclinical research and treatment for metastatic of hepatocelluar carcinoma.